These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15660337)

  • 1. Uric acid in chronic heart failure.
    Doehner W; Anker SD
    Semin Nephrol; 2005 Jan; 25(1):61-6. PubMed ID: 15660337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
    Doehner W; Schoene N; Rauchhaus M; Leyva-Leon F; Pavitt DV; Reaveley DA; Schuler G; Coats AJ; Anker SD; Hambrecht R
    Circulation; 2002 Jun; 105(22):2619-24. PubMed ID: 12045167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
    Harzand A; Tamariz L; Hare JM
    Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
    Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
    Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance.
    Doehner W; Rauchhaus M; Florea VG; Sharma R; Bolger AP; Davos CH; Coats AJ; Anker SD
    Am Heart J; 2001 May; 141(5):792-9. PubMed ID: 11320368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?
    Duan X; Ling F
    Med Hypotheses; 2008; 70(3):578-81. PubMed ID: 17689199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Borghi C; Palazzuoli A; Landolfo M; Cosentino E
    Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
    Gavin AR; Struthers AD
    Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanthine oxidase inhibitors the unappreciated treatment for heart failure.
    Ellestad MH
    Cardiovasc Hematol Disord Drug Targets; 2007 Dec; 7(4):291-4. PubMed ID: 18220728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure.
    Joseph J; Giczewska A; Alhanti B; Cheema AK; Handy DE; Mann DL; Loscalzo J; Givertz MM
    J Physiol Biochem; 2021 May; 77(2):295-304. PubMed ID: 33595776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol and endothelial function in heart failure: future or fantasy?
    Landmesser U; Drexler H
    Circulation; 2002 Jul; 106(2):173-5. PubMed ID: 12105153
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimal uric acid reduction to improve vascular endothelial function in patients with chronic heart failure complicated by hyperuricemia.
    Naganuma J; Sakuma M; Kitahara K; Kato T; Yokomachi J; Yamauchi F; Inoue R; Iida K; Kohno Y; Inoue K; Koshiji N; Abe S; Toyoda S; Inoue T;
    Hypertens Res; 2023 Mar; 46(3):688-696. PubMed ID: 36539463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure.
    Niizeki T; Takeishi Y; Arimoto T; Okuyama H; Nozaki N; Hirono O; Tsunoda Y; Watanabe T; Nitobe J; Miyashita T; Takahashi H; Koyama Y; Kubota I
    J Cardiol; 2006 May; 47(5):219-28. PubMed ID: 16764328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study.
    Givertz MM; Mann DL; Lee KL; Ibarra JC; Velazquez EJ; Hernandez AF; Mascette AM; Braunwald E
    Circ Heart Fail; 2013 Jul; 6(4):862-8. PubMed ID: 23861505
    [No Abstract]   [Full Text] [Related]  

  • 19. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.
    Gavin AD; Struthers AD
    Heart; 2005 Jun; 91(6):749-53. PubMed ID: 15894768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
    Reyes AJ; Leary WP
    Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.